$
2. 78
-0.02
-0.7143%
$
55.86M Market Cap
- P/E Ratio
- Div Yield
61,416 Volume
- Eps
$ 2.8
Previous Close Investors:
Want to track BEST and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Opus Genetics: A Resounding Study Success Merits A Higher Valuation
Opus Genetics receives a Buy rating following >30% stock surge on positive Phase 1/2 data for OPGx-BEST1 in BEST1-related retinal diseases. OPGx-BEST1 showed clinically meaningful visual improvements and strong safety in all Cohort 1 patients, with greater gains in less advanced disease. IRD's pipeline targets large, underserved markets with no approved therapies; cash runway extends into 2029, supporting ongoing pivotal studies.
Seekingalpha | 1 week ago
Opus Genetics, Inc. (IRD) Discusses Topline Results From Cohort 1 of BEST1 Phase I/II Gene Therapy Trial Transcript
Opus Genetics, Inc. (IRD) Discusses Topline Results From Cohort 1 of BEST1 Phase I/II Gene Therapy Trial Transcript
Seekingalpha | 1 week ago
